Trials / Enrolling By Invitation
Enrolling By InvitationNCT06634355
Placental Transfer of Sugammadex in the Human Placental Perfusion Model
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 16 (estimated)
- Sponsor
- Universitaire Ziekenhuizen KU Leuven · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Preclinical research raised concern regarding the foetal effects of using sugammadex during pregnancy. However, to the best of our knowledge, the placental transfer of sugammadex has never been measured. As these data would be critical in assessing the foetal effects after maternal administration of sugammadex, it is warranted to measure the placental transfer of sugammadex. The aim of this project is to measure the placental transfer of sugammadex in the human placenta by using the ex vivo human placenta perfusion model.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sugammadex | In an ex-vivo placenta perfusion study, placental transfer of sugammadex is measured. |
Timeline
- Start date
- 2025-03-17
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2024-10-09
- Last updated
- 2026-01-09
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06634355. Inclusion in this directory is not an endorsement.